Advanced Accelerator Applications – AAA | Bridging science with life

Advanced Accelerator Applications Announces Health Canada Approval for Lutathera™, a Treatment for Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) - February 2019

First ever approved Peptide Receptor Radionuclide Therapy in Canada. Neuroendocrine tumors are rare malignancies that affect approximately 12,000-15,000 Canadians.

A worldwide presence

AAA operates in Belgium, Canada, France, Germany, Israel, Italy, the Netherlands, Poland, Portugal, Spain, Switzerland, UK and USA while its distribution network covers more than 30 countries. Please point to any of the locations to pull up specific details about each facility.

Products

Advanced Accelerator Applications (AAA) develops, produces and commercializes molecular nuclear medicine, diagnostic and therapeutic products in the fields of oncology (cancer), neurology, cardiology and infectious & inflammatory diseases.

Pipeline

We are developing a pipeline of theragnostic pairings for oncology indications. AAA’s theragnostic platform involves radiolabeling a targeting molecule with either gallium Ga 68 for diagnostic use, or lutetium Lu 177 for therapy.

Making personalised treatment a reality.

AAA is a European leader in the production and commercialization of PET (Positron Emission Tomography) and SPECT (Single Photon Emission Tomography) radiopharmaceuticals and is able to produce and deliver both commercial drugs and research products.

Discover

Our documentary about Molecular Nuclear Medicine and cancer.

Molecular Nuclear Medicine with a 22’ documentary from the history of radioactivity and cancer to the most modern Theragnostic techniques. You will understand how SPECT and PET work, and how Radio Metabolic Therapy can treat cancer.